Trial
NCT03850535
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Idasanutlin
Why stopped
Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-21